The Incidence of Postoperative Complications after Gastrectomy Increases in Proportion to the Amount of Preoperative Visceral Fat
Table 1
Characteristics of the patients.
Variable
Visceral fat area (cm2)
value
0–49 n = 91
50–99 n = 160
100–149 n = 187
≥150 n = 128
Age
Continuous
64.8 ± 13.9
66.8 ± 11.1
67.3 ± 8.9
69.8 ± 9.4
0.0065
Sex
Male
36 (39.6%)
92 (57.5%)
129 (69.0%)
114 (89.1%)
<0.0001
BMI (kg/m2)
≥25
0 (0%)
13 (8.1%)
46 (24.6%)
72 (56.3%)
<0.0001
Subcutaneous fat (cm2)
Continuous
58.6 ± 5.0
112 ± 3.8
133 ± 3.5
153 ± 4.2
<0.0001
ASA score
≥3
4 (4.4%)
14 (8.8%)
14 (7.5%)
19 (14.8%)
0.042
DM
Yes
3 (3.3%)
13 (8.1%)
21 (11.2%)
31 (24.2%)
<0.0001
Sarcopenia
Yes
49 (53.9%)
114 (71.3%)
117 (62.6%)
74 (62.5%)
0.025
NAC
Yes
18 (19.8%)
17 (10.6%)
28 (15.0%)
8 (6.3%)
0.015
cStage
I
58 (63.7%)
110 (68.8%)
115 (61.5%)
81 (63.3%)
0.035
II
11 (12.1%)
24 (15.0%)
39 (20.9%)
33 (25.8%)
III
22 (24.2%)
26 (16.3%)
33 (17.7%)
14 (10.9%)
Serum albumin (g/dL)
≤3.5
23 (25.3%)
28 (17.5%)
25 (13.4%)
14 (10.9%)
0.023
Operative procedure
DG
61 (67.0%)
120 (75.0%)
129 (69.0%)
83 (64.8%)
0.28
TG
30 (33.0%)
40 (25.0%)
58 (31.0%)
45 (35.2%)
Surgical approach
Laparoscopic
83 (91.2%)
146 (91.3%)
177 (94.7%)
105 (82.0%)
0.0028
Open
2 (2.2%)
2 (1.3%)
7 (3.7%)
7 (5.5%)
Robotic
6 (6.6%)
12 (7.5%)
3 (1.6%)
16 (12.5%)
Lymph node dissection
D1+
43 (47.3%)
75 (46.9%)
90 (48.1%)
64 (50.0%)
0.96
D2
48 (52.7%)
85 (53.1%)
97 (51.9%)
64 (50.0%)
BMI: body mass index; ASA: American Society of Anesthesiologists; DM: diabetes mellitus; NAC: neoadjuvant chemotherapy; TG: total gastrectomy; DG: distal gastrectomy.
